Tagged with Access

Pharma Olaf Weppner, General Manager of AbbVie Switzerland, highlights AbbVie’s intended foray into oncology, the importance of immunology to the group, the challenges and opportunities of the Swiss market and his own motivations for working in the industry. Mr. Weppner, you were appointed General Manager of AbbVie Switzerland less than a…

Health Alberto Hechanova, president of the Drugstore Association of the Philippines (DSAP), discusses the competitive landscape of the country, highlighting the main challenges and opportunities for independent drugstores. In addition, he explains why being a member of the association can impact business success. Mr Hechanova, could you please introduce yourself and…

Pharma The Singapore Association of Pharmaceutical Industries’ (SAPI) recently appointed president, Ti Hwei How highlights several unique attributes that distinguish Singapore’s renowned healthcare system from others around the world, while delineating three potential avenues for expanding patient access to innovative medicines. To begin, Ti Hwei, how would you characterize the specificities…

Pharma The Mexican pharmaceutical market’s capacity to change dramatically in a short period of time means that both innovators and generics companies must think strategically and “play their cards right” in order to succeed. From 2014 to 2015, the total Mexican pharmaceutical market displayed a strong 5.3 percent growth to reach…

Pharma Axel B. Müller, managing director of Intergenerika, the Swiss generics association, reveals the penetration rate of generics in Switzerland; why generics are a safe, and smarter choice, manufactured to modern standards with affordable prices; and the threat of government forcing generic companies to benchmark their prices to nine European countries…

Pharma Building on the continuous improvements of the Federal Commission for the Protection Against Sanitary Risk (Cofepris) over the last few years, its recently-appointed Federal Commissioner Julio Sánchez y Tépoz reveals his strategy to further strengthen and develop the Commission’s processes and international leadership, and foster a more transparent, technical, efficient…

Pharma Eisai’s Czech Republic’s Operations Manager discusses the role Eisai plays in the country, the transparency of the pharma industry in the region, and his aspirations for the future. What does the Czech market have to offer Eisai compared to its neighboring countries? The Czech Republic is one of the most…

Pharma Following regulatory changes, CSL Behring is now able to offer plasma fractionation and purification services to Italy’s public healthcare sector for the first time. General manager Oliver Schmitt discusses the added value and savings CSL Behring can offer in this service segment and the benefits its newest generation of innovative…

Pharma As Egypt continues to grapple with the proliferation of the hepatitis C virus, fresh treatment, prevention and market access pathways are now being applied. Given the severity of Egypt’s hepatitis C epidemic, the national campaign against viral hepatitis remains Egypt’s top healthcare priority. According to Roche’s regional general manager, Ehab…

Pharma Concerted efforts are, at last, being made to redraw the rulebook and tidy up a local regulatory landscape long renowned for its torpor, dysfunction and ineffectuality. The Egyptian pharmaceutical market is currently regulated by the Ministry of Health itself, with all issues related to pharmaceuticals falling under the responsibility of…

Pharma GE Healthcare Italy’s Marco Campione discusses patient access to innovation, synergies between pharma and medtech in companion diagnostics, and partnering with the Italian healthcare system. You have been working at GE Healthcare for 18 years now, having risen up the ranks through various departments. What was at the top of…

Pharma In an exclusive discussion with Focus Reports, Egyptian Minister of Health, Dr. Ahmed El Din Rady sets out his blueprint for improving the nation’s welfare and securing positive public health outcomes with a 4-point plan based on human capital development, accessibility, countering hepatitis C, and large-scale infrastructural intervention. My foremost…